Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00279617 · ClinicalTrials.gov registry record · Phase 3
Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks
A Phase 3 study of Panic Disorder, sponsored by Lindner Center of HOPE.
- Completed
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00279617 is a Phase 3 study of Panic Disorder that has completed, run by Lindner Center of HOPE. The registered enrollment target is 15 participants, below the 222-participant average among 25 other Panic Disorder trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00279617, a Phase 3 study of Panic Disorder, has completed, sponsored by Lindner Center of HOPE.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this research study is to determine whether the drug Levetiracetam (Keppra™) is effective in the prevention of panic attacks. The drug Levetiracetam (Keppra™) has been approved for the treatment of seizures by the U.S. Federal Food and Drug Administration (FDA) and is available by prescription. Levetiracetam has not been approved by the FDA for the treatment of panic disorder.
Conditions Studied
Interventions
- DRUG levetiracetam
Study Locations (1)
Ohio
- University of Cincinnati Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-01 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00279617
The ClinicalTrials.gov registry entry for NCT00279617 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 25 other Panic Disorder trials with a reported enrollment target (93% lower). The listed sponsor is Lindner Center of HOPE, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Panic Disorder appearing as the primary indexed condition, and to 1 intervention - of which levetiracetam is the first listed.
NCT00279617 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00279617 about?
NCT00279617 is a clinical study titled "Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks". The main purpose of this research study is to determine whether the drug Levetiracetam (Keppra™) is effective in the prevention of panic attacks. The drug Levetiracetam (Keppra™) has been approved for the treatment of seizures by the U.S. Federal Food and Drug Administration (FDA) and is available b...
What is the current status of trial NCT00279617?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2006-01. Estimated completion is 2009-03.
What conditions does trial NCT00279617 study?
This clinical trial studies the following conditions: Panic Disorder.
What interventions are being tested in trial NCT00279617?
The interventions under investigation include: levetiracetam (DRUG).
Who is sponsoring clinical trial NCT00279617?
This trial is sponsored by Lindner Center of HOPE, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00279617 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Panic Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Telephone-Based Care Management Program for Individuals With Anxiety Disorders
COMPLETED · Phase 3
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
-
CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy
RECRUITING · NA
-
Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method
RECRUITING · NA
-
Comparative Effectiveness of Internet-based Versus Parent-Coached Cognitive-Behavioral Therapy For Children and Adolescents With Anxiety and OCD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.